MeSH term
Frequency | Condition_Probility | Humans | 185 | 0.0 |
Male | 88 | 0.0 |
Middle Aged | 75 | 0.0 |
Adolescent | 49 | 0.0 |
Adult | 90 | 0.0 |
Aged | 41 | 0.0 |
Antigen-Antibody Complex/blood | 4 | 12.0 |
Complement 3d/analysis | 3 | 20.0 |
*Complement Activation | 4 | 1.0 |
Female | 95 | 0.0 |
Prognosis | 18 | 0.0 |
Research Support, Non-U.S. Gov't | 70 | 0.0 |
Animals | 22 | 0.0 |
Cattle | 2 | 0.0 |
Cells, Cultured | 3 | 0.0 |
Oxidation-Reduction | 3 | 0.0 |
Antibodies, Bacterial/*blood | 2 | 4.0 |
Antigen-Antibody Complex/*blood | 24 | 44.0 |
Child | 34 | 0.0 |
English Abstract | 35 | 0.0 |
Complement 3a/analysis | 2 | 11.0 |
Complement 4/analysis | 6 | 2.0 |
Enzyme-Linked Immunosorbent Assay | 18 | 0.0 |
Autoantibodies/blood | 2 | 1.0 |
Complement/analysis | 4 | 2.0 |
Fluorescent Antibody Technique | 7 | 0.0 |
Immunosuppression | 2 | 1.0 |
Acute Disease | 10 | 0.0 |
Comparative Study | 32 | 0.0 |
Time Factors | 12 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Pregnancy | 7 | 0.0 |
Child, Preschool | 14 | 0.0 |
Mycobacterium tuberculosis/*immunology | 2 | 3.0 |
Disease-Free Survival | 2 | 0.0 |
Precipitation | 5 | 3.0 |
Prednisone/therapeutic use | 2 | 1.0 |
Amino Acid Sequence | 3 | 0.0 |
Molecular Sequence Data | 3 | 0.0 |
Antibody Specificity | 10 | 0.0 |
Reference Values | 7 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Immunoglobulin A/blood | 2 | 1.0 |
Immunoglobulin G/blood | 4 | 1.0 |
Immunoglobulin M/blood | 4 | 3.0 |
Immunoglobulins/*blood | 5 | 15.0 |
Prospective Studies | 7 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
*Kidney Transplantation | 4 | 0.0 |
Neutrophils/immunology | 3 | 1.0 |
Phagocytosis/drug effects | 2 | 2.0 |
Rats | 3 | 0.0 |
Chronic Disease | 10 | 0.0 |
Antibody Formation/immunology | 2 | 4.0 |
Leprosy/*immunology | 3 | 12.0 |
Evaluation Studies | 3 | 0.0 |
Cytological Techniques | 2 | 5.0 |
Double-Blind Method | 2 | 0.0 |
Infant | 7 | 0.0 |
Antigen-Antibody Complex/*analysis | 84 | 53.0 |
C-Reactive Protein/analysis | 2 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Aging/*immunology | 2 | 1.0 |
Nigeria | 4 | 6.0 |
Complement 3/analysis | 10 | 3.0 |
Rabbits | 5 | 0.0 |
Cross-Sectional Studies | 2 | 0.0 |
Immunoglobulin G/analysis | 16 | 4.0 |
Immunoglobulin M/*analysis | 3 | 6.0 |
Molecular Weight | 3 | 0.0 |
Polyethylene Glycols | 4 | 4.0 |
Antigen-Antibody Complex/*immunology | 11 | 13.0 |
Combined Modality Therapy | 3 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Immune Complex Diseases/*immunology | 2 | 50.0 |
Age Factors | 4 | 0.0 |
Neoplasm Staging | 5 | 0.0 |
Sex Factors | 3 | 0.0 |
Antibodies, Helminth/blood | 2 | 10.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Schistosoma mansoni/immunology | 2 | 7.0 |
Conjunctiva/*pathology | 3 | 75.0 |
Infant, Newborn | 2 | 0.0 |
Prevalence | 3 | 0.0 |
Biological Markers/blood | 2 | 0.0 |
Remission Induction | 3 | 0.0 |
Leukocyte Count | 4 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Leukocytes/*immunology | 3 | 2.0 |
Lymphocyte Activation | 3 | 0.0 |
Blood Donors | 2 | 0.0 |
Follow-Up Studies | 5 | 0.0 |
Immunoglobulin A/*analysis | 3 | 5.0 |
Research Support, U.S. Gov't, P.H.S. | 18 | 0.0 |
Immunoglobulin G/*analysis | 4 | 5.0 |
Pre-Eclampsia/*immunology | 2 | 14.0 |
Precipitin Tests | 3 | 0.0 |
Blood Platelets/immunology | 2 | 2.0 |
Platelet Count | 2 | 0.0 |
Staphylococcal Protein A/*immunology | 2 | 28.0 |
Autoantibodies/analysis | 5 | 2.0 |
Immunoglobulins/*analysis | 4 | 4.0 |
Myocardium/immunology | 2 | 18.0 |
Rheumatoid Factor/*analysis | 3 | 14.0 |
Antigen-Antibody Complex/analysis | 10 | 9.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
Lung Neoplasms/*immunology | 2 | 4.0 |
Arthritis, Rheumatoid/*immunology | 4 | 1.0 |
Rheumatoid Factor/analysis | 7 | 11.0 |
Hepatitis B/immunology | 2 | 18.0 |
Rosette Formation | 2 | 0.0 |
Autoantibodies/*biosynthesis | 2 | 3.0 |
HIV Seropositivity/complications/*immunology | 2 | 18.0 |
Hemophilia A/complications/*immunology | 2 | 14.0 |
*Antigen-Antibody Complex | 10 | 16.0 |
Hepatitis B Surface Antigens/*analysis | 2 | 6.0 |
Complement 3/*immunology | 2 | 3.0 |
Solubility | 2 | 0.0 |
Autoantibodies/*analysis | 5 | 2.0 |
Blood Platelets/*immunology | 2 | 2.0 |
Antigen-Antibody Complex/*analysis/immunology | 4 | 66.0 |
Leukoplakia, Oral/immunology | 2 | 66.0 |
Biopsy | 3 | 0.0 |
Immunoglobulins/analysis | 3 | 1.0 |
Kinetics | 2 | 0.0 |
Lupus Erythematosus, Systemic/*immunology | 3 | 2.0 |
Radioimmunoassay | 7 | 0.0 |
Immunosorbent Techniques | 2 | 0.0 |
Purpura, Thrombocytopenic/immunology/*therapy | 2 | 50.0 |
Fasting | 2 | 0.0 |
Antibodies, Anti-Idiotypic/analysis | 2 | 7.0 |
Immunoglobulin G | 2 | 1.0 |
Antibodies, Antinuclear/analysis | 3 | 4.0 |
Hodgkin Disease/*immunology | 2 | 7.0 |
Isoelectric Focusing | 3 | 0.0 |
Antigen-Antibody Complex/*isolation & purification | 2 | 25.0 |
Neoplasms/*immunology | 5 | 4.0 |
Recurrence | 3 | 0.0 |
Diabetes Mellitus, Type 1/*immunology | 2 | 2.0 |
Reference Standards | 2 | 0.0 |
Breast Neoplasms/*immunology | 2 | 3.0 |
Complement 3d | 4 | 5.0 |
Clinical Trials | 2 | 0.0 |
Immunoglobulin M/analysis | 4 | 1.0 |
Cell Line | 2 | 0.0 |
Serum Globulins | 2 | 33.0 |
Complement 3/metabolism | 2 | 0.0 |
Immunoglobulin G/immunology | 5 | 1.0 |
Immunity, Cellular | 3 | 0.0 |
Receptors, Complement 3b | 2 | 0.0 |
Immune Sera/immunology | 2 | 1.0 |
Polyethylene Glycols/diagnostic use | 2 | 25.0 |
Immune Complex Diseases/*therapy | 2 | 100.0 |
Plasmapheresis/*methods | 2 | 25.0 |
Complement 1q | 18 | 17.0 |
Complement Activating Enzymes | 3 | 21.0 |
Complement/metabolism | 2 | 2.0 |
Complement Activating Enzymes/analysis | 7 | 23.0 |
Analysis of Variance | 2 | 0.0 |
Complement 1/analysis | 3 | 6.0 |
Protein Binding | 3 | 0.0 |
Immunoglobulin G/biosynthesis | 2 | 1.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Chromatography, Gel | 2 | 0.0 |
Complement Activating Enzymes/*immunology | 2 | 22.0 |
Glomerulonephritis/immunology | 2 | 8.0 |
Lupus Erythematosus, Systemic/immunology | 5 | 4.0 |
Complement Activating Enzymes/metabolism | 4 | 14.0 |
Immunoassay/methods | 2 | 3.0 |
Leukemia/*immunology | 2 | 5.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
Heparin/pharmacology | 2 | 0.0 |
Arthritis, Rheumatoid/immunology | 3 | 3.0 |
Complement 3/immunology | 2 | 2.0 |
Liver Diseases/*immunology | 2 | 10.0 |
Chorionic Gonadotropin/blood | 2 | 2.0 |
Hydatidiform Mole/immunology | 2 | 66.0 |
Antigen-Antibody Complex/*analysis/metabolism | 2 | 40.0 |
Centrifugation, Density Gradient | 4 | 1.0 |
*Collectins | 3 | 18.0 |
Complement Activating Enzymes/immunology | 2 | 20.0 |
Breast Neoplasms/immunology | 3 | 8.0 |
Carcinoma, Bronchogenic/immunology | 2 | 100.0 |
Cervix Neoplasms/immunology | 2 | 25.0 |
Lung Neoplasms/immunology | 2 | 14.0 |
Uterine Neoplasms/immunology | 2 | 40.0 |
*Enzyme-Linked Immunosorbent Assay | 2 | 2.0 |
*Immunoenzyme Techniques | 3 | 2.0 |
Antigen-Antibody Complex/*metabolism | 2 | 2.0 |
Complement Fixation Tests | 6 | 6.0 |
Antibodies, Bacterial/analysis | 2 | 5.0 |
Immunoglobulin A/analysis | 4 | 2.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
Spermatozoa/*immunology | 2 | 4.0 |
Carcinoembryonic Antigen/analysis | 2 | 1.0 |
Nephelometry and Turbidimetry | 2 | 2.0 |
Phagocytosis | 3 | 0.0 |
Complement/immunology | 2 | 2.0 |
Immunodiffusion | 2 | 0.0 |
Glomerulonephritis/*immunology | 2 | 5.0 |
Kidney/pathology | 2 | 1.0 |
Nephritis/immunology | 2 | 22.0 |
*Graft Rejection | 2 | 2.0 |
